

## Could you help us develop research for head and neck cancer?

*No research experience needed.*



We would like to talk to people with experience of head and neck cancer – either as a **patient, family/friend, or carer**. Your thoughts and opinions are invaluable and will help us develop a **new head and neck cancer research trial**, called **immunoREACH**.

No previous experience of clinical research or patient and public involvement in research is needed. We will provide background information and any other support you may need to be able to contribute.

One of the most important questions for people who have been through radiotherapy is ‘how do we know if the cancer is going to come back’? We want to find more accurate and effective ways of detecting when cancer has come back through research. ImmunoREACH aims to test if a simple blood test, or ‘liquid biopsy’, can detect the return of cancer earlier than usual imaging (i.e., CT scan). All of us have some of our genetic material (DNA) floating in our blood, which can be detected when a blood sample is taken. In people with cancer, some of the DNA found in the blood comes from the person’s cancer cells. By looking for DNA from cancer cells, this could mean the cancer is detected sooner. This could improve outcomes by giving more patients the option of surgery and the potential for earlier treatment with immunotherapy.



We would like to know how you feel about this research to make sure the reasons why we want to run this trial are easy to understand, and that we are asking the best research questions for patients. Communicating the research background, along with the possible risks and benefits in a clear and understandable way, is essential to ensure that immunoREACH is designed so that everyone has the opportunity to take part. This includes underserved groups. We would like your help, as someone with experience of head and neck cancer, to make this happen.

If you are willing to share your thoughts and views, we would like you to join us for an **online discussion** lasting up to **60 minutes**. Reimbursement for your time is available as a **one-off payment of £30**. The discussion group will involve up to 12 people and will be hosted by the trial team (photos on the next page). The group discussion will be recorded for note-taking purposes only and recordings will be deleted afterwards. You will not be identifiable from these notes and you may use a pseudonym if you prefer.



**Planned discussion groups will be held on:**



**Thursday 29th February at 16:00 – 17:00**

**Tuesday 5<sup>th</sup> March at 14:00 – 15:00**

**Wednesday 6<sup>th</sup> March at 19:00 – 20:00**

If you are interested, would like some more information or an informal chat about this study, please contact us by emailing [immunoREACH-ICRCTSU@icr.ac.uk](mailto:immunoREACH-ICRCTSU@icr.ac.uk).

This Trial is being developed by the [Clinical Trials and Statistics Unit](#) at The Institute of Cancer Research (ICR). The lead researchers are [Dr Ben O'Leary](#) (Royal Marsden Hospital) and [Professor Judith Bliss](#) (ICR)

### Meet the Trial Team



**Dr Ben O'Leary**

Consultant in Clinical  
Oncology, RMH



**Dr Mai Bishr**

Academic Clinical Fellow in  
Clinical Oncology, RMH



**Amber Emmerson**

Trial Manager,  
ICR-CTSU



**Christy Toms**

Clinical Trial Programme  
Manager, ICR-CTSU

*Any contact details you provide will be stored securely according to the ICR's privacy policy (<https://www.icr.ac.uk/legal/privacy>). Details will be shared with researchers based at the Royal Marsden and ICR and will only be used to arrange discussion groups and provide updates on this project.*